Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Moodys
Medtronic
AstraZeneca
Boehringer Ingelheim

Last Updated: December 7, 2021

Volunteer for clinical trials for flortaucipir f-18 at ClinicalTrialExchange

DrugPatentWatch Database Preview

Flortaucipir f-18 - Generic Drug Details

➤ Subscribe for complete access

« Back to Dashboard

What are the generic drug sources for flortaucipir f-18 and what is the scope of patent protection?

Flortaucipir f-18 is the generic ingredient in one branded drug marketed by Avid Radiopharms Inc and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Flortaucipir f-18 has eighteen patent family members in nine countries.

One supplier is listed for this compound.

Summary for flortaucipir f-18
International Patents:18
US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 1
Clinical Trials: 19
Patent Applications: 7
What excipients (inactive ingredients) are in flortaucipir f-18?flortaucipir f-18 excipients list
DailyMed Link:flortaucipir f-18 at DailyMed
Recent Clinical Trials for flortaucipir f-18

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Neil M Rofsky, MD, MHAPhase 2
Avid RadiopharmaceuticalsPhase 3
The Cleveland ClinicPhase 1

See all flortaucipir f-18 clinical trials

US Patents and Regulatory Information for flortaucipir f-18

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Avid Radiopharms Inc TAUVID flortaucipir f-18 SOLUTION;INTRAVENOUS 212123-001 May 28, 2020 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Avid Radiopharms Inc TAUVID flortaucipir f-18 SOLUTION;INTRAVENOUS 212123-002 May 28, 2020 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Avid Radiopharms Inc TAUVID flortaucipir f-18 SOLUTION;INTRAVENOUS 212123-001 May 28, 2020 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Avid Radiopharms Inc TAUVID flortaucipir f-18 SOLUTION;INTRAVENOUS 212123-002 May 28, 2020 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for flortaucipir f-18

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2009102498 ⤷  Try it Free
European Patent Office 2247558 ⤷  Try it Free
European Patent Office 2599763 ⤷  Try it Free
China 107011342 ⤷  Try it Free
Australia 2012381042 ⤷  Try it Free
South Korea 20150002854 ⤷  Try it Free
European Patent Office 2852572 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Colorcon
Johnson and Johnson
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.